Viking Therapeutics, Inc. (VKTX): Price and Financial Metrics
Viking Therapeutics, Inc. (VKTX)
Today's Latest Price: $6.02 USD
Updated Sep 23 4:00pm
Add VKTX to WatchlistSign Up
POWR Components:
Trade Grade Buy & Hold Grade Peer Grade Industry Rank
Industry Rank:
Ranked of 233 in Medical - Pharmaceuticals
See all "A" rated Strong Buy stocks
VKTX Stock Price Chart Technical Analysis Charts
VKTX Price/Volume Stats
| Current price | $6.02 | 52-week high | $8.87 |
| Prev. close | $6.67 | 52-week low | $3.26 |
| Day low | $6.00 | Volume | 1,187,272 |
| Day high | $6.69 | Avg. volume | 1,436,549 |
| 50-day MA | $6.99 | Dividend yield | N/A |
| 200-day MA | $6.69 | Market Cap | 438.00M |
Viking Therapeutics, Inc. (VKTX) Company Bio
Viking Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of novel therapies for metabolic and endocrine disorders. Its lead clinical program, VK5211, is an orally available, non-steroidal selective androgen receptor modulator in Phase II development for the treatment of patients recovering from non-elective hip fracture surgery; in Phase I clinical trials for improving lean body mass; and in pre-clinical trial for improving bone mineral density, bone mineral content, bone strength, and other measures. The company is also developing VK2809, an orally available, tissue and receptor-subtype selective agonist of the thyroid hormone receptor beta, which is in a Phase II clinical trial for the treatment of patients with hypercholesterolemia and fatty liver disease; and in a Phase I clinical trial to treat patients who suffer from glycogen storage disease type Ia. In addition, it is developing VK0214 for X-linked adrenoleukodystrophy, which is in pre-clinical stage. Viking Therapeutics, Inc. was founded in 2012 and is based in San Diego, California.
Loading social stream, please wait...